Longer-term results from the BENEFIT trial show sustained minimal residual disease negativity in newly diagnosed, ...

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

To Jagannath, cure means long periods of disease-free survival as defined by minimal residual disease (MRD) criteria, 10 -5 ...

Adult bacterial meningitis carries high mortality and neurological complications, especially from Listeria and Streptococcus ...

Clofutriben is a novel, once-daily, oral HSD-1 inhibitor that reduces excess intracellular cortisol, a new precision approach ...

Learn more about whether Harrow, Inc. or Ocular Therapeutix, Inc. is a better investment based on AAII's A+ Investor grades, ...

The latest weekly national rulings for Jan. 1-7 are out and Jose R. Gonzalez was reported as suspended for 18 months ...

A company claiming to be “America’s Largest Ophthalmic Pharmacy” has issued a recall for multiple eye drop products for the ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...

C4 Therapeutics Inc. (NASDAQ: CCCC) is one of the best biotech penny stocks to buy according to analysts. On December 17, ...